Gerald Harris, MD
Ophthalmic Plastic and Reconstructive Surgery · Milwaukee, WINPI 1629029467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,000 of the $12,814 with a category attached, or 85.8%. Amgen accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $11,554 and has fallen 91.6% since, to $975 in 2024.
Across 10 payments — averaging $1281.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$12K
- Janssen Research & Development, LLC$975
Across 10 payments — averaging $37,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$374K
What the payments were for
- Consulting fees$1,26010%
- Speaking & faculty fees$11,00086%
- Travel & lodging$3082%
- Food & beverage$2462%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $11,839 |
| Janssen Research & Development, LLC | 1 | $975 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$285
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorometholone | 12 | $714 |
| ErythromycinErythromycin Base | 26 | $308 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Milwaukee
- Sang HongMilwaukee$43K
- Neda EsmailiMilwaukee$78
- Cathy BurkatMadison$17K
- Mark LucarelliMadison$11K
- Mark DuffyGreen Bay$315
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.